We're here for you and your family at Arkansas Children's – and at home. Tell us more about yourself for a personalized experience.
Our comprehensive pediatric cardiac program is home to state-of-the-art technologies, world-class cardiologists and innovative procedures. This unmatched combination of resources makes us the region’s leading provider of comprehensive cardiovascular care for our most important patient: your child.
Arkansas Children’s Foundation has promoted long-time fundraising executive Enid Olvey, CFRE, to the position of president.
Jason Williams, Psy.D., M.S.Ed. will lead work to improve pediatric mental and behavioral health statewide.
The 2022 Miracle Ball, a shared project of Arkansas Children’s Hospital (ACH) Auxiliary and Arkansas Children’s Foundation, raised more than $870,000 benefiting Arkansas Children’s Hospital.
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days by mouth difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia.
With an uptick in respiratory illnesses, it's important to know the differences between RSV, flu and COVID-19 viruses and when it's time to take your child to a primary care doctor or the emergency room.
We know that healthcare can be complicated, so we make it as easy as possible to access primary and specialty care.